Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Terns Pharmaceuticals Inc TERN

Healthcare
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors... see more

Recent & Breaking News (NDAQ:TERN)

Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire 6 days ago

Terns Announces Pricing of Upsized $150.15 Million Public Offering

GlobeNewswire 8 days ago

Terns Announces Proposed Public Offering

GlobeNewswire 9 days ago

Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

GlobeNewswire 10 days ago

Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire August 5, 2024

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire August 1, 2024

Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition

GlobeNewswire July 29, 2024

Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation

GlobeNewswire June 21, 2024

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire June 3, 2024

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

GlobeNewswire May 30, 2024

Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day

GlobeNewswire May 17, 2024

Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire May 13, 2024

Terns Pharmaceuticals Announces Leadership Changes

GlobeNewswire May 8, 2024

Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024

GlobeNewswire May 7, 2024

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire May 3, 2024

Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation

GlobeNewswire April 29, 2024

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

GlobeNewswire April 10, 2024

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

GlobeNewswire March 14, 2024

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

GlobeNewswire March 11, 2024

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire March 7, 2024